Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 12 of 12 publications.

Musara P, Milford C, Shapley-Quinn MK, Weinrib R, Mutero P, Odoom E, Mgodi NM, Chirenje ZM, Hanif H, Clark MR, Smit J, van der Straten A, Montgomery ET, Quatro Study Team. Preferences and acceptability of vaginal delivery forms for HIV prevention among women, male partners and key informants in South Africa and Zimbabwe: qualitative findings. AIDS Behav. 2020 Jun 25. doi: 10.1007/s10461-020-02949-4

Browne EN, Montgomery ET, Mansfield C, Boeri M, Mange B, Beksinska M, Schwartz JL, Clark MR, Doncel GF, Smit J, Chirenje ZM, van der Straten A. Efficacy is not everything: eliciting women's preferences for a vaginal HIV prevention product using a discrete-choice experiment. AIDS Behav. 2020 May;24(5):1443-51. doi: 10.1007/s10461-019-02715-1

Weinrib R, Browne EN, Shapley-Quinn MK, van der Straten A, Beksinska M, Mgodi N, Musara P, Mphili N, Schwartz JL, Ju S, Hanif H, Montgomery ET, Quatro Study Team. Perspectives from young South African and Zimbabwean women on attributes of four (placebo) vaginal microbicide delivery forms. AIDS Behav. 2020 Feb;24(2):637-47. doi: 10.1007/s10461-019-02576-8

Hackshaw MD, Bui CL, Ladner A, Tu N, Zahidu I, Ritchey ME, Salas M. Review of survival, safety, and clinical outcomes in HER2+ metastatic gastric cancer following the administration of trastuzumab post-trastuzumab gastric cancer. Cancer Treat Res Commun. 2020;24(2020). doi: 10.1016/j.ctarc.2020.100189

Minnis AM, Roberts ST, Agot K, Weinrib R, Ahmed K, Manenzhe K, Owino F, van der Straten A, TRIO Study Team. Young women's ratings of three placebo multipurpose prevention technologies for HIV and pregnancy prevention in a randomized, cross‑over study in Kenya and South Africa. AIDS Behav. 2018 Aug;22(8):2662-73. doi: 10.1007/s10461-018-2078-5

Weinrib R, Minnis A, Agot KA, Ahmed K, Owino F, Manenzhe K, Cheng H, van der Straten A. End-users' product preference across three multipurpose prevention technology delivery forms: baseline results from young women in Kenya and South Africa. AIDS Behav. 2018 Jan;22(1):133-45. doi: 10.1007/s10461-017-1911-6

O'Leary A, DiNenno E, Honeycutt A, Allaire B, Neuwahl S, Hicks K, Sansom S. Contribution of anal sex to HIV prevalence among heterosexuals: a modeling analysis. AIDS Behav. 2017 Jan 5. doi: 10.1007/s10461-016-1635-z

Loftus EV, Davis KL, Wang CC, Dastani H, Luo A. Treatment patterns, complications, and disease relapse in a real-world population of patients with moderate-to-severe ulcerative colitis initiating immunomodulator therapy. Inflamm Bowel Dis. 2014 Aug;20(8):1361-7. doi: 10.1097/MIB.0000000000000089

Fletcher FE, Vidrine DJ, Tami-Maury I, Danysh HE, King RM, Buchberg M, Arduino RC, Gritz ER. Cervical cancer screening adherence among HIV-positive female smokers from a comprehensive HIV clinic. AIDS Behav. 2014 Mar;18(3):544-54. doi: 10.1007/s10461-013-0480-6

Long MD, Hutfless S, Kappelman MD, Khalili H, Kaplan GG, Bernstein CN, Colombel JF, Gower-Rousseau C, Herrinton L, Velayos F, Loftus EVJr, Ananthakrishnan AN, Nguyen GC, Sonnenberg A, Chan A, Sandler RS, Atreja A, Shah SA, Rothman KJ, Leleiko NS, Bright R, Boffetta P, Myers KD, Sands BE. Challenges in designing a national surveillance program for inflammatory bowel disease in the United States. Inflamm Bowel Dis. 2014 Feb;20(2):398-415. doi: 10.1097/01.MIB.0000435441.30107.8b

Debanjali M, Hodgkins P, Yen L, Solomon D, Davis KL, Cohen R. Adherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitis: impact on all-cause healthcare costs. Inflamm Bowel Dis. 2009 Dec 1;15(12):S32.

Whittington D, Sur D, Cook J, Chatterjee S, Maskery B, Lahiri M, Poulos C, Boral S, Nyamete A, Deen J, Ochiai L, Bhattacharya SK. Rethinking cholera and typhoid vaccination policies for the poor: private demand in Kolkata, India. World Dev. 2009 Feb 1;37(2):399-409.